A typical Investment Bank, Mergers & Acquisitions (M&A) Advisory Firm provides a range of investment banking services tailored to the needs of healthcare and life sciences organizations. These services include mergers and acquisitions, corporate finance, strategic advisory services, consulting, institutional M&A and corporate valuations. There are few firms, however, that also provide strategic partnering services as a value added component and differentiator.
Industry partnerships are the life blood for life sciences firms, especially those in pre-revenue stage. Compounded with the challenging capital markets in recent years for capital raises, more and more life science companies are looking at ways to grow and finance their company and R&D programs through non-diluted means. Typically, partnerships involve a transfer of technology from a small biotech to a large company in return for cash and/or co-development rights. These partnerships can involve significant sums of upfront and downstream cash flows and often represent the first major validation of the technology by an established pharmaceutical or large biotechnology company. The transactions represent non-dilutive funding as financing that does not require the sale of your company’s shares, and hence does not cause dilution of the existing shareholders. Objective Capital Partners helps life sciences clients build, negotiate, and implement essential strategic alliances that are essential to a company’s growth.
For more information on how Objective Capital can help you, contact our Healthcare & Life Science team at firstname.lastname@example.org.